Stifel Financial Corp grew its position in Tocagen Inc (NASDAQ:TOCA) by 34.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,392 shares of the company’s stock after purchasing an additional 6,698 shares during the quarter. Stifel Financial Corp owned approximately 0.13% of Tocagen worth $215,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Meeder Asset Management Inc. raised its holdings in shares of Tocagen by 162.8% in the 4th quarter. Meeder Asset Management Inc. now owns 9,961 shares of the company’s stock valued at $82,000 after purchasing an additional 6,170 shares in the last quarter. Stratos Wealth Partners LTD. grew its position in shares of Tocagen by 9.0% in the 4th quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock valued at $94,000 after buying an additional 949 shares during the last quarter. Caption Management LLC purchased a new position in shares of Tocagen in the 4th quarter valued at $98,000. Citadel Advisors LLC purchased a new position in shares of Tocagen in the 3rd quarter valued at $251,000. Finally, Rhumbline Advisers grew its position in shares of Tocagen by 50.7% in the 4th quarter. Rhumbline Advisers now owns 23,303 shares of the company’s stock valued at $191,000 after buying an additional 7,843 shares during the last quarter. Institutional investors and hedge funds own 36.53% of the company’s stock.

NASDAQ TOCA opened at $8.47 on Friday. The company has a quick ratio of 5.91, a current ratio of 5.91 and a debt-to-equity ratio of 0.45. Tocagen Inc has a 12 month low of $6.47 and a 12 month high of $15.80.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, February 27th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.35). Tocagen had a negative return on equity of 92.56% and a negative net margin of 271.43%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, equities research analysts anticipate that Tocagen Inc will post -2.99 earnings per share for the current fiscal year.

A number of research analysts recently commented on TOCA shares. Robert W. Baird started coverage on shares of Tocagen in a research report on Friday, January 18th. They issued an “outperform” rating and a $20.00 target price on the stock. B. Riley started coverage on shares of Tocagen in a research report on Monday, December 31st. They issued a “buy” rating and a $22.00 target price on the stock. Zacks Investment Research raised shares of Tocagen from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Tuesday, January 15th. Leerink Swann started coverage on shares of Tocagen in a research report on Monday, April 15th. They issued a “market perform” rating and a $10.26 target price on the stock. Finally, Svb Leerink started coverage on shares of Tocagen in a research report on Monday, April 15th. They issued a “market perform” rating and a $11.00 target price on the stock. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Tocagen presently has a consensus rating of “Buy” and a consensus price target of $18.58.

TRADEMARK VIOLATION NOTICE: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2019/04/21/stifel-financial-corp-has-215000-stake-in-tocagen-inc-toca.html.

Tocagen Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Read More: Special Dividends

Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).

Institutional Ownership by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.